• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation.

作者信息

Pei Xu-Ying, Huang Qiang, Luo Ling-Jie, Sun Hai-Lu, Liu Jing, Sun Yu-Qian, Mo Xiao-Dong, Lv Meng, Liu Dai-Hong, Ma Hong-Yan, Wu Yan-Wei, Xu Lan-Ping, Wang Yu, Zhang Xiao-Hui, Chen Liang, Huang Xiao-Jun

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing.

School of Medicine, Shanghai University, Shanghai 200444, China; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases.

出版信息

Haematologica. 2025 Apr 1;110(4):1005-1009. doi: 10.3324/haematol.2024.286265. Epub 2024 Nov 28.

DOI:10.3324/haematol.2024.286265
PMID:39605206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959248/
Abstract
摘要

相似文献

1
Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation.来特莫韦预防巨细胞病毒感染与单倍体干细胞移植后发生移植后淋巴细胞增殖性疾病的风险相关。
Haematologica. 2025 Apr 1;110(4):1005-1009. doi: 10.3324/haematol.2024.286265. Epub 2024 Nov 28.
2
[Clinical analysis of the usefulness of letermovir for prevention of cytomegalovirus infection after haploidentical hematopoietic stem cell transplantation].来特莫韦预防单倍体相合造血干细胞移植后巨细胞病毒感染的有效性临床分析
Zhonghua Nei Ke Za Zhi. 2023 Jul 1;62(7):826-832. doi: 10.3760/cma.j.cn112138-20221204-00904.
3
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.异基因干细胞移植后第 100 天停用洛韦特停药与 CMV 相关死亡率增加相关。
Transplant Cell Ther. 2022 Aug;28(8):510.e1-510.e9. doi: 10.1016/j.jtct.2022.05.020. Epub 2022 May 20.
4
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.来特莫韦作为异基因造血细胞移植后巨细胞病毒感染的二级预防：单中心经验。
Eur J Haematol. 2024 Oct;113(4):477-484. doi: 10.1111/ejh.14258. Epub 2024 Jun 21.
5
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.来特莫韦用于预防单倍体相合及配型不合的成年供者异基因造血细胞移植中巨细胞病毒再激活，移植后使用环磷酰胺预防移植物抗宿主病。
Transplant Cell Ther. 2021 Jan;27(1):85.e1-85.e6. doi: 10.1016/j.bbmt.2020.10.009. Epub 2020 Oct 11.
6
Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.胸器官移植中的巨细胞病毒预防：来特莫韦预防的单中心评估。
J Heart Lung Transplant. 2022 Apr;41(4):508-515. doi: 10.1016/j.healun.2021.12.005. Epub 2021 Dec 22.
7
Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.来特莫韦用于异基因造血细胞移植受者原发性和继发性巨细胞病毒预防的真实世界经验。
Transpl Infect Dis. 2019 Dec;21(6):e13187. doi: 10.1111/tid.13187. Epub 2019 Oct 21.
8
Extended duration letermovir in allogeneic hematopoietic stem cell transplant.延长疗程的来特莫韦用于异基因造血干细胞移植。
Transpl Immunol. 2023 Dec;81:101936. doi: 10.1016/j.trim.2023.101936. Epub 2023 Sep 26.
9
Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.真实世界经验：在使用T细胞清除作为移植物抗宿主病预防措施的情况下，研究来特莫韦用于高危异基因造血干细胞患者巨细胞病毒预防的疗效。
Transpl Immunol. 2023 Feb;76:101769. doi: 10.1016/j.trim.2022.101769. Epub 2022 Dec 2.
10
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation.同种异体造血干细胞移植后预防巨细胞病毒感染引起的 EBV 再激活增加。
J Hematol Oncol. 2024 Oct 12;17(1):94. doi: 10.1186/s13045-024-01612-y.

引用本文的文献

1
Efficacy and safety of primary letermovir prophylaxis for cytomegalovirus infection in paediatric patients undergoing allogeneic transplantation: a single-centre, retrospective, real-world analysis.来特莫韦对接受异基因移植的儿科患者巨细胞病毒感染进行一级预防的疗效和安全性：一项单中心、回顾性、真实世界分析。
Clin Hematol Int. 2025 Mar 14;7(1):36-46. doi: 10.46989/001c.131683. eCollection 2025.
2
Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell transplantation in the letermovir era for cytomegalovirus prophylaxis.在使用来特莫韦预防巨细胞病毒的异基因造血干细胞移植时代，由于采用抢先使用利妥昔单抗治疗，爱泼斯坦-巴尔病毒再激活增加，但移植后淋巴细胞增生性疾病的发生率相似。
Bone Marrow Transplant. 2025 May;60(5):721-724. doi: 10.1038/s41409-025-02542-0. Epub 2025 Mar 3.

本文引用的文献

1
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染的疗效和安全性。
Blood Sci. 2024 Jan 10;6(1):e00178. doi: 10.1097/BS9.0000000000000178. eCollection 2024 Jan.
2
Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy.同种异体造血干细胞移植后巨细胞病毒感染的细胞因子特异性 T 细胞过继免疫治疗及疗效影响因素
Am J Hematol. 2022 Jun 1;97(6):762-769. doi: 10.1002/ajh.26535. Epub 2022 Mar 25.
3
Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
同种异体干细胞移植后巨细胞病毒和 Epstein-Barr 病毒的共同再激活与预后不良相关。
Front Immunol. 2021 Feb 16;11:620891. doi: 10.3389/fimmu.2020.620891. eCollection 2020.
4
Clinical application of Epstein-Barr virus DNA loads in Epstein-Barr virus-associated diseases: A cohort study.EB 病毒 DNA 载量在 EB 病毒相关性疾病中的临床应用：一项队列研究。
J Infect. 2021 Jan;82(1):105-111. doi: 10.1016/j.jinf.2020.11.027. Epub 2020 Nov 26.
5
Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.移植后患者巨细胞病毒和 Epstein-Barr 病毒合并感染率及临床结局数据：文献系统综述。
Transpl Infect Dis. 2020 Dec;22(6):e13396. doi: 10.1111/tid.13396. Epub 2020 Jul 27.
6
First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation.供体源性人巨细胞病毒（HCMV）特异性 T 细胞的一线治疗可通过促进异基因干细胞移植后抗病毒免疫来减少持续性 HCMV 感染。
Clin Infect Dis. 2020 Mar 17;70(7):1429-1437. doi: 10.1093/cid/ciz368.
7
Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy.成人非恶性肿瘤相关性噬血细胞性淋巴组织细胞增生症的治疗结局和预后因素。
Haematologica. 2019 Feb;104(2):269-276. doi: 10.3324/haematol.2018.198655. Epub 2018 Sep 13.
8
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials.移植受者中用于临床试验的耐更昔洛韦和难治性巨细胞病毒感染和疾病的定义。
Clin Infect Dis. 2019 Apr 8;68(8):1420-1426. doi: 10.1093/cid/ciy696.
9
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
10
The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.异基因造血细胞移植后双链DNA病毒检测的累积负担与死亡率增加相关。
Blood. 2017 Apr 20;129(16):2316-2325. doi: 10.1182/blood-2016-10-748426. Epub 2017 Feb 16.